{"fetched":"2026-09-28","previousFetched":"2026-09-21","keepDays":90,"changes":[{"detected":"2026-09-28","drugId":"plerixafor","nct":"NCT00967785","title":"A Phase I Study of Mozobil in the Treatment of Patients With WHIMS","phases":["PHASE1","PHASE2"],"sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","primaryCompletion":"2026-06-25","kind":"primary-completion","from":"2026-08-06","to":"2026-06-25"},{"detected":"2026-09-28","drugId":"raloxifene","nct":"NCT02188745","title":"ER Reactivation Therapy for Breast Cancer","phases":["PHASE2"],"sponsor":"Dartmouth-Hitchcock Medical Center","primaryCompletion":"2024-01-05","kind":"results-posted"},{"detected":"2026-09-28","drugId":"blinatumomab","nct":"NCT02458014","title":"Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2025-09-16","kind":"results-posted"},{"detected":"2026-09-28","drugId":"entrectinib","nct":"NCT02650401","title":"Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options","phases":["PHASE1","PHASE2"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2027-06-30","kind":"primary-completion","from":"2026-06-30","to":"2027-06-30"},{"detected":"2026-09-28","drugId":"gilteritinib","nct":"NCT03182244","title":"A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation","phases":["PHASE3"],"sponsor":"Astellas Pharma Inc","primaryCompletion":"2023-12-25","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-28","drugId":"envafolimab","nct":"NCT03478488","title":"Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC","phases":["PHASE3"],"sponsor":"3D Medicines (Sichuan) Co., Ltd.","primaryCompletion":"2024-09-10","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-28","drugId":"abiraterone","nct":"NCT03568656","title":"Study to Evaluate CCS1477 in Advanced Tumours","phases":["PHASE1","PHASE2"],"sponsor":"CellCentric Ltd.","primaryCompletion":"2025-07-06","kind":"results-posted"},{"detected":"2026-09-28","drugId":"avelumab","nct":"NCT03573648","title":"Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer","phases":["PHASE2"],"sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","primaryCompletion":"2026-12-30","kind":"primary-completion","from":"2026-09-30","to":"2026-12-30"},{"detected":"2026-09-28","drugId":"eprenetapopt","nct":"NCT03588078","title":"Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine","phases":["PHASE1","PHASE2"],"sponsor":"Groupe Francophone des Myelodysplasies","primaryCompletion":"2020-05-01","kind":"status","from":"UNKNOWN","to":"COMPLETED"},{"detected":"2026-09-28","drugId":"cediranib","nct":"NCT03741426","title":"WIRE - Novel Treatments in Renal Cell Cancer","phases":["PHASE2"],"sponsor":"CCTU- Cancer Theme","primaryCompletion":"2027-12-30","kind":"status","from":"UNKNOWN","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"cediranib","nct":"NCT03741426","title":"WIRE - Novel Treatments in Renal Cell Cancer","phases":["PHASE2"],"sponsor":"CCTU- Cancer Theme","primaryCompletion":"2027-12-30","kind":"primary-completion","from":"2025-11-30","to":"2027-12-30"},{"detected":"2026-09-28","drugId":"rilvegostomig","nct":"NCT03741426","title":"WIRE - Novel Treatments in Renal Cell Cancer","phases":["PHASE2"],"sponsor":"CCTU- Cancer Theme","primaryCompletion":"2027-12-30","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"abemaciclib","nct":"NCT03969706","title":"Abemaciclib in Patients With Oligodendroglioma","phases":["PHASE2"],"sponsor":"Stephen Bagley, MD, MSCE","primaryCompletion":"2024-09-15","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-28","drugId":"abemaciclib","nct":"NCT03969706","title":"Abemaciclib in Patients With Oligodendroglioma","phases":["PHASE2"],"sponsor":"Stephen Bagley, MD, MSCE","primaryCompletion":"2024-09-15","kind":"results-posted"},{"detected":"2026-09-28","drugId":"abemaciclib","nct":"NCT03969706","title":"Abemaciclib in Patients With Oligodendroglioma","phases":["PHASE2"],"sponsor":"Stephen Bagley, MD, MSCE","primaryCompletion":"2024-09-15","kind":"primary-completion","from":"2025-05-15","to":"2024-09-15"},{"detected":"2026-09-28","drugId":"carfilzomib","nct":"NCT04096066","title":"A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant","phases":["PHASE3"],"sponsor":"Fondazione EMN Italy Onlus","primaryCompletion":"2027-09-01","kind":"primary-completion","from":"2026-01-01","to":"2027-09-01"},{"detected":"2026-09-28","drugId":"denosumab","nct":"NCT04232657","title":"Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI","phases":["PHASE2"],"sponsor":"VA Office of Research and Development","primaryCompletion":"2026-08-24","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-28","drugId":"denosumab","nct":"NCT04232657","title":"Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI","phases":["PHASE2"],"sponsor":"VA Office of Research and Development","primaryCompletion":"2026-08-24","kind":"primary-completion","from":"2026-08-01","to":"2026-08-24"},{"detected":"2026-09-28","drugId":"darolutamide","nct":"NCT04335682","title":"Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide","phases":["PHASE2"],"sponsor":"Alliance Foundation Trials, LLC.","primaryCompletion":"2025-09-01","kind":"results-posted"},{"detected":"2026-09-28","drugId":"belzutifan","nct":"NCT04489771","title":"A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)","phases":["PHASE2"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2023-02-10","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-28","drugId":"metyrapone","nct":"NCT04501874","title":"A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder","phases":["PHASE2"],"sponsor":"Embera NeuroTherapeutics, Inc.","primaryCompletion":"2022-07-27","kind":"results-posted"},{"detected":"2026-09-28","drugId":"lipegfilgrastim","nct":"NCT04506554","title":"A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer","phases":["PHASE2"],"sponsor":"Fox Chase Cancer Center","primaryCompletion":"2027-05","kind":"primary-completion","from":"2026-05","to":"2027-05"},{"detected":"2026-09-28","drugId":"motixafortide","nct":"NCT04543071","title":"Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma","phases":["PHASE2"],"sponsor":"Columbia University","primaryCompletion":"2028-06","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"dostarlimab","nct":"NCT04584255","title":"Niraparib + Dostarlimab In BRCA Mutated Breast Cancer","phases":["PHASE2"],"sponsor":"Dana-Farber Cancer Institute","primaryCompletion":"2025-07-01","kind":"results-posted"},{"detected":"2026-09-28","drugId":"fianlimab","nct":"NCT04590326","title":"A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab","phases":["PHASE1","PHASE2"],"sponsor":"Regeneron Pharmaceuticals","primaryCompletion":"2028-11-08","kind":"primary-completion","from":"2027-03-25","to":"2028-11-08"},{"detected":"2026-09-28","drugId":"belzutifan","nct":"NCT04626479","title":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","phases":["PHASE1","PHASE2"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2026-08-10","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-28","drugId":"belzutifan","nct":"NCT04626479","title":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","phases":["PHASE1","PHASE2"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2026-08-10","kind":"primary-completion","from":"2026-08-21","to":"2026-08-10"},{"detected":"2026-09-28","drugId":"belzutifan","nct":"NCT04626518","title":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","phases":["PHASE1","PHASE2"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2026-07-23","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-28","drugId":"belzutifan","nct":"NCT04626518","title":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","phases":["PHASE1","PHASE2"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2026-07-23","kind":"primary-completion","from":"2026-08-21","to":"2026-07-23"},{"detected":"2026-09-28","drugId":"pirtobrutinib","nct":"NCT04662255","title":"Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)","phases":["PHASE3"],"sponsor":"Loxo Oncology, Inc.","primaryCompletion":"2027-11","kind":"primary-completion","from":"2027-01","to":"2027-11"},{"detected":"2026-09-28","drugId":"polatuzumab-vedotin","nct":"NCT04679012","title":"Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation","phases":["PHASE2"],"sponsor":"Weill Medical College of Cornell University","primaryCompletion":"2027-01","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"polatuzumab-vedotin","nct":"NCT04679012","title":"Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation","phases":["PHASE2"],"sponsor":"Weill Medical College of Cornell University","primaryCompletion":"2027-01","kind":"primary-completion","from":"2026-09","to":"2027-01"},{"detected":"2026-09-28","drugId":"belantamab-mafodotin","nct":"NCT04876248","title":"Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant","phases":["PHASE2"],"sponsor":"Roswell Park Cancer Institute","primaryCompletion":"2027-07-29","kind":"primary-completion","from":"2026-10-21","to":"2027-07-29"},{"detected":"2026-09-28","drugId":"belzutifan","nct":"NCT04924075","title":"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)","phases":["PHASE2"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2032-11-18","kind":"primary-completion","from":"2029-12-27","to":"2032-11-18"},{"detected":"2026-09-28","drugId":"asciminib","nct":"NCT04925479","title":"Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia","phases":["PHASE1","PHASE2"],"sponsor":"Novartis Pharmaceuticals","primaryCompletion":"2027-09-02","kind":"primary-completion","from":"2027-09-21","to":"2027-09-02"},{"detected":"2026-09-28","drugId":"pirtobrutinib","nct":"NCT05023980","title":"A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","phases":["PHASE3"],"sponsor":"Loxo Oncology, Inc.","primaryCompletion":"2025-07-11","kind":"results-posted"},{"detected":"2026-09-28","drugId":"teclistamab","nct":"NCT05083169","title":"A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma","phases":["PHASE3"],"sponsor":"Janssen Research & Development, LLC","primaryCompletion":"2025-08-01","kind":"primary-completion","from":"2025-09-15","to":"2025-08-01"},{"detected":"2026-09-28","drugId":"acasunlimab","nct":"NCT05117242","title":"Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer","phases":["PHASE2"],"sponsor":"Genmab","primaryCompletion":"2024-12-02","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"TERMINATED"},{"detected":"2026-09-28","drugId":"jdq443","nct":"NCT05132075","title":"Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer","phases":["PHASE3"],"sponsor":"Novartis Pharmaceuticals","primaryCompletion":"2026-09-03","kind":"primary-completion","from":"2026-08-25","to":"2026-09-03"},{"detected":"2026-09-28","drugId":"zanidatamab","nct":"NCT05152147","title":"A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers","phases":["PHASE3"],"sponsor":"Jazz Pharmaceuticals","primaryCompletion":"2026-07-15","kind":"primary-completion","from":"2026-09-30","to":"2026-07-15"},{"detected":"2026-09-28","drugId":"histamine-dihydrochloride","nct":"NCT05156047","title":"A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia","phases":["PHASE3"],"sponsor":"Harmony Biosciences Management, Inc.","primaryCompletion":"2023-09-08","kind":"results-posted"},{"detected":"2026-09-28","drugId":"teclistamab","nct":"NCT05231629","title":"Sequential Therapy in Multiple Myeloma Guided by MRD Assessments","phases":["PHASE2"],"sponsor":"University of Alabama at Birmingham","primaryCompletion":"2028-09","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"teclistamab","nct":"NCT05231629","title":"Sequential Therapy in Multiple Myeloma Guided by MRD Assessments","phases":["PHASE2"],"sponsor":"University of Alabama at Birmingham","primaryCompletion":"2028-09","kind":"primary-completion","from":"2027-12","to":"2028-09"},{"detected":"2026-09-28","drugId":"relacorilant","nct":"NCT05257408","title":"Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer","phases":["PHASE3"],"sponsor":"Corcept Therapeutics","primaryCompletion":"2025-03-31","kind":"results-posted"},{"detected":"2026-09-28","drugId":"relacorilant","nct":"NCT05257408","title":"Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer","phases":["PHASE3"],"sponsor":"Corcept Therapeutics","primaryCompletion":"2025-03-31","kind":"primary-completion","from":"2025-03-24","to":"2025-03-31"},{"detected":"2026-09-28","drugId":"retifanlimab","nct":"NCT05287113","title":"Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","phases":["PHASE2"],"sponsor":"Incyte Biosciences International Sàrl","primaryCompletion":"2025-03-14","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-28","drugId":"talazoparib","nct":"NCT05327010","title":"Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2026-12-31","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"sonrotoclax","nct":"NCT05471843","title":"Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma","phases":["PHASE1","PHASE2"],"sponsor":"BeOne Medicines","primaryCompletion":"2025-07-18","kind":"results-posted"},{"detected":"2026-09-28","drugId":"breast-cancer-index","nct":"NCT05528133","title":"Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer","phases":["PHASE2"],"sponsor":"H. Lee Moffitt Cancer Center and Research Institute","primaryCompletion":"2029-09","kind":"primary-completion","from":"2028-05","to":"2029-09"},{"detected":"2026-09-28","drugId":"mezigdomide","nct":"NCT05552976","title":"A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)","phases":["PHASE3"],"sponsor":"Bristol-Myers Squibb","primaryCompletion":"2026-09-28","kind":"primary-completion","from":"2026-07-18","to":"2026-09-28"},{"detected":"2026-09-28","drugId":"teclistamab","nct":"NCT05572229","title":"Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma","phases":["PHASE2"],"sponsor":"University Hospital, Lille","primaryCompletion":"2027-06","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"teclistamab","nct":"NCT05572229","title":"Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma","phases":["PHASE2"],"sponsor":"University Hospital, Lille","primaryCompletion":"2027-06","kind":"primary-completion","from":"2026-04","to":"2027-06"},{"detected":"2026-09-28","drugId":"abemaciclib","nct":"NCT05708235","title":"A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population","phases":["PHASE2"],"sponsor":"MedSIR","primaryCompletion":"2028-06-30","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"pyrotinib","nct":"NCT05745740","title":"A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation","phases":["PHASE1","PHASE2"],"sponsor":"RemeGen Co., Ltd.","primaryCompletion":"2027-12-01","kind":"status","from":"UNKNOWN","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"pyrotinib","nct":"NCT05745740","title":"A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation","phases":["PHASE1","PHASE2"],"sponsor":"RemeGen Co., Ltd.","primaryCompletion":"2027-12-01","kind":"primary-completion","from":"2025-12","to":"2027-12-01"},{"detected":"2026-09-28","drugId":"envafolimab","nct":"NCT05752136","title":"Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma","phases":["PHASE3"],"sponsor":"Sir Run Run Shaw Hospital","primaryCompletion":"2026-11-01","kind":"primary-completion","from":"2025-04","to":"2026-11-01"},{"detected":"2026-09-28","drugId":"glofitamab","nct":"NCT05783596","title":"Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma","phases":["PHASE2"],"sponsor":"Reid Merryman, MD","primaryCompletion":"2026-05-27","kind":"primary-completion","from":"2026-08","to":"2026-05-27"},{"detected":"2026-09-28","drugId":"glofitamab","nct":"NCT05861050","title":"Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma","phases":["PHASE1","PHASE2"],"sponsor":"City of Hope Medical Center","primaryCompletion":"2027-02-01","kind":"status","from":"RECRUITING","to":"SUSPENDED"},{"detected":"2026-09-28","drugId":"azd5863","nct":"NCT06005493","title":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","phases":["PHASE1","PHASE2"],"sponsor":"AstraZeneca","primaryCompletion":"2029-03-16","kind":"primary-completion","from":"2027-07-16","to":"2029-03-16"},{"detected":"2026-09-28","drugId":"rilvegostomig","nct":"NCT06005493","title":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","phases":["PHASE1","PHASE2"],"sponsor":"AstraZeneca","primaryCompletion":"2029-03-16","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"memantine","nct":"NCT06041789","title":"Effect of Acetylcholinesterase Inhibitors on Bone Metabolism","phases":["PHASE2"],"sponsor":"Duke University","primaryCompletion":"2027-09","kind":"primary-completion","from":"2026-11","to":"2027-09"},{"detected":"2026-09-28","drugId":"dostarlimab","nct":"NCT06062420","title":"A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202","phases":["PHASE2"],"sponsor":"GlaxoSmithKline","primaryCompletion":"2026-09-10","kind":"primary-completion","from":"2026-09-01","to":"2026-09-10"},{"detected":"2026-09-28","drugId":"budigalimab","nct":"NCT06109272","title":"A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)","phases":["PHASE2","PHASE3"],"sponsor":"AbbVie","primaryCompletion":"2027-01","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"budigalimab","nct":"NCT06109272","title":"A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)","phases":["PHASE2","PHASE3"],"sponsor":"AbbVie","primaryCompletion":"2027-01","kind":"primary-completion","from":"2030-09","to":"2027-01"},{"detected":"2026-09-28","drugId":"crizotinib","nct":"NCT06140836","title":"A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)","phases":["PHASE3"],"sponsor":"Bristol-Myers Squibb","primaryCompletion":"2027-02-16","kind":"primary-completion","from":"2026-03-13","to":"2027-02-16"},{"detected":"2026-09-28","drugId":"brexucabtagene-autoleucel","nct":"NCT06144606","title":"Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)","phases":["PHASE2"],"sponsor":"H. Lee Moffitt Cancer Center and Research Institute","primaryCompletion":"2031-07-29","kind":"primary-completion","from":"2028-11-15","to":"2031-07-29"},{"detected":"2026-09-28","drugId":"zongertinib","nct":"NCT06151574","title":"Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment","phases":["PHASE3"],"sponsor":"Boehringer Ingelheim","primaryCompletion":"2026-12-10","kind":"primary-completion","from":"2026-09-02","to":"2026-12-10"},{"detected":"2026-09-28","drugId":"daratumumab","nct":"NCT06169215","title":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2026-04-15","kind":"primary-completion","from":"2026-09-30","to":"2026-04-15"},{"detected":"2026-09-28","drugId":"bendamustine","nct":"NCT06284122","title":"Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5","phases":["PHASE3"],"sponsor":"The Lymphoma Academic Research Organisation","primaryCompletion":"2028-11","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"abiraterone","nct":"NCT06369610","title":"Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer","phases":["PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2028-07-29","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"abiraterone","nct":"NCT06369610","title":"Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer","phases":["PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2028-07-29","kind":"primary-completion","from":"2027-04-22","to":"2028-07-29"},{"detected":"2026-09-28","drugId":"dalpiciclib","nct":"NCT06447623","title":"Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer","phases":["PHASE3"],"sponsor":"Fudan University","primaryCompletion":"2027-02-01","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"petosemtamab","nct":"NCT06525220","title":"A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)","phases":["PHASE3"],"sponsor":"Merus B.V.","primaryCompletion":"2028-01","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"epcoritamab","nct":"NCT06563596","title":"Epco, Zanu, Ritux for R/R FL or MZL","phases":["PHASE2"],"sponsor":"Reid Merryman, MD","primaryCompletion":"2030-03-01","kind":"primary-completion","from":"2028-03-01","to":"2030-03-01"},{"detected":"2026-09-28","drugId":"datopotamab-deruxtecan","nct":"NCT06564844","title":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features","phases":["PHASE3"],"sponsor":"AstraZeneca","primaryCompletion":"2026-07-10","kind":"primary-completion","from":"2027-06-30","to":"2026-07-10"},{"detected":"2026-09-28","drugId":"trabedersen","nct":"NCT06579196","title":"Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1","phases":["PHASE1","PHASE2"],"sponsor":"University of Nebraska","primaryCompletion":"2028-03","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"hmpl-760","nct":"NCT06601504","title":"Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","phases":["PHASE2"],"sponsor":"Hutchmed","primaryCompletion":"2026-05-23","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-28","drugId":"hmpl-760","nct":"NCT06601504","title":"Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","phases":["PHASE2"],"sponsor":"Hutchmed","primaryCompletion":"2026-05-23","kind":"primary-completion","from":"2026-05-12","to":"2026-05-23"},{"detected":"2026-09-28","drugId":"shr-8068","nct":"NCT06618664","title":"A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02)","phases":["PHASE3"],"sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","primaryCompletion":"2026-10","kind":"primary-completion","from":"2026-09","to":"2026-10"},{"detected":"2026-09-28","drugId":"raludotatug-deruxtecan","nct":"NCT06660654","title":"A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)","phases":["PHASE2"],"sponsor":"Daiichi Sankyo","primaryCompletion":"2029-12-30","kind":"primary-completion","from":"2027-09-30","to":"2029-12-30"},{"detected":"2026-09-28","drugId":"pirtobrutinib","nct":"NCT06721013","title":"A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia","phases":["PHASE1","PHASE2"],"sponsor":"Eli Lilly and Company","primaryCompletion":"2028-02","kind":"primary-completion","from":"2028-05","to":"2028-02"},{"detected":"2026-09-28","drugId":"nalirifox","nct":"NCT06736717","title":"Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer","phases":["PHASE1","PHASE2"],"sponsor":"University of Kansas Medical Center","primaryCompletion":"2026-07-16","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"nalirifox","nct":"NCT06736717","title":"Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer","phases":["PHASE1","PHASE2"],"sponsor":"University of Kansas Medical Center","primaryCompletion":"2026-07-16","kind":"primary-completion","from":"2026-07","to":"2026-07-16"},{"detected":"2026-09-28","drugId":"atigotatug","nct":"NCT06773910","title":"BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)","phases":["PHASE2"],"sponsor":"SCRI Development Innovations, LLC","primaryCompletion":"2032-05","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"evofosfamide","nct":"NCT06836726","title":"Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer","phases":["PHASE2"],"sponsor":"University Health Network, Toronto","primaryCompletion":"2028-10-01","kind":"primary-completion","from":"2028-05-27","to":"2028-10-01"},{"detected":"2026-09-28","drugId":"floxuridine","nct":"NCT06888063","title":"Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside the Liver Treatable by Surgery","phases":["PHASE2"],"sponsor":"Erasmus Medical Center","primaryCompletion":"2028-09","kind":"primary-completion","from":"2026-09","to":"2028-09"},{"detected":"2026-09-28","drugId":"megestrol-progestins","nct":"NCT06905210","title":"Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris","phases":["PHASE3"],"sponsor":"Eurofarma Laboratorios S.A.","primaryCompletion":"2027-02","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"shr-a1912","nct":"NCT06929624","title":"A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma","phases":["PHASE3"],"sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","primaryCompletion":"2027-03","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"ponsegromab","nct":"NCT06989437","title":"A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue","phases":["PHASE2","PHASE3"],"sponsor":"Pfizer","primaryCompletion":"2028-01-23","kind":"primary-completion","from":"2028-01-17","to":"2028-01-23"},{"detected":"2026-09-28","drugId":"flotufolastat","nct":"NCT07025369","title":"Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial","phases":["PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2029-01-01","kind":"primary-completion","from":"2026-12-31","to":"2029-01-01"},{"detected":"2026-09-28","drugId":"flot","nct":"NCT07069712","title":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","phases":["PHASE2"],"sponsor":"AstraZeneca","primaryCompletion":"2027-11-09","kind":"primary-completion","from":"2027-11-03","to":"2027-11-09"},{"detected":"2026-09-28","drugId":"nogapendekin-alfa","nct":"NCT07123727","title":"A Study to Examine Anktiva for the Treatment of COVID-19.","phases":["PHASE2"],"sponsor":"ImmunityBio, Inc.","primaryCompletion":"2027-03","kind":"primary-completion","from":"2026-07","to":"2027-03"},{"detected":"2026-09-28","drugId":"metyrapone","nct":"NCT07138274","title":"Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS","phases":["PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2031-06","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"trastuzumab-deruxtecan","nct":"NCT07150208","title":"T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2027-09","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"aumolertinib","nct":"NCT07183189","title":"A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC","phases":["PHASE3"],"sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","primaryCompletion":"2032-11","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"gecacitinib","nct":"NCT07185633","title":"Study of Gecacitinib-corticosteroid as First-line Therapy for Grade II-IV Acute Graft Versus Host Disease","phases":["PHASE2"],"sponsor":"Bin Gu","primaryCompletion":"2027-10-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"gecacitinib","nct":"NCT07185633","title":"Study of Gecacitinib-corticosteroid as First-line Therapy for Grade II-IV Acute Graft Versus Host Disease","phases":["PHASE2"],"sponsor":"Bin Gu","primaryCompletion":"2027-10-01","kind":"primary-completion","from":"2026-10-01","to":"2027-10-01"},{"detected":"2026-09-28","drugId":"jnj-79635322","nct":"NCT07266441","title":"A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma","phases":["PHASE2"],"sponsor":"Janssen Research & Development, LLC","primaryCompletion":"2027-06-14","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"folfiri","nct":"NCT07271355","title":"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial","phases":["PHASE3"],"sponsor":"City of Hope Medical Center","primaryCompletion":"2031-02-28","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"capox","nct":"NCT07291401","title":"Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC","phases":["PHASE2"],"sponsor":"Zhongnan Hospital","primaryCompletion":"2027-01-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"belzutifan","nct":"NCT07405164","title":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)","phases":["PHASE3"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2034-04-22","kind":"primary-completion","from":"2034-01-14","to":"2034-04-22"},{"detected":"2026-09-28","drugId":"hlx11","nct":"NCT07407920","title":"Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-09-30","kind":"primary-completion","from":"2026-09-30","to":"2028-09-30"},{"detected":"2026-09-28","drugId":"penpulimab","nct":"NCT07419880","title":"Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2027-12-31","kind":"primary-completion","from":"2027-01-30","to":"2027-12-31"},{"detected":"2026-09-28","drugId":"raloxifene","nct":"NCT07470606","title":"Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain","phases":["PHASE2"],"sponsor":"The University of Texas Health Science Center at San Antonio","primaryCompletion":"2030-07","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"raloxifene","nct":"NCT07470606","title":"Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain","phases":["PHASE2"],"sponsor":"The University of Texas Health Science Center at San Antonio","primaryCompletion":"2030-07","kind":"primary-completion","from":"2030-03","to":"2030-07"},{"detected":"2026-09-28","drugId":"mosunetuzumab","nct":"NCT07548450","title":"Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)","phases":["PHASE2"],"sponsor":"University of Utah","primaryCompletion":"2034-11","kind":"primary-completion","from":"2034-06","to":"2034-11"},{"detected":"2026-09-28","drugId":"navlimetostat","nct":"NCT07579221","title":"Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer","phases":["PHASE1","PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2029-08-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"selumetinib","nct":"NCT07619521","title":"Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma","phases":["PHASE1","PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2028-09-08","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"selumetinib","nct":"NCT07619521","title":"Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma","phases":["PHASE1","PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2028-09-08","kind":"primary-completion","from":"2026-10-30","to":"2028-09-08"},{"detected":"2026-09-28","drugId":"tqb2930","nct":"NCT07653685","title":"A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.","phases":["PHASE1","PHASE2"],"sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","primaryCompletion":"2027-06","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"pylarify","nct":"NCT07686380","title":"IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2029-01-30","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"capox","nct":"NCT07728019","title":"Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM","phases":["PHASE2"],"sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","primaryCompletion":"2029-06-30","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"signatera","nct":"NCT07750158","title":"Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease","phases":["PHASE3"],"sponsor":"Exelixis","primaryCompletion":"2030-04-05","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"telisotuzumab-adizutecan","nct":"NCT07769502","title":"A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers","phases":["PHASE2"],"sponsor":"AbbVie","primaryCompletion":"2028-09","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"telisotuzumab-adizutecan","nct":"NCT07769502","title":"A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers","phases":["PHASE2"],"sponsor":"AbbVie","primaryCompletion":"2028-09","kind":"primary-completion","from":"2028-11","to":"2028-09"},{"detected":"2026-09-28","drugId":"raludotatug-deruxtecan","nct":"NCT07776691","title":"A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)","phases":["PHASE3"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2032-03-19","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"nogapendekin-alfa","nct":"NCT07783789","title":"NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With Sepsis","phases":["PHASE2"],"sponsor":"ImmunityBio, Inc.","primaryCompletion":"2028-05-12","kind":"primary-completion","from":"2027-10-12","to":"2028-05-12"},{"detected":"2026-09-28","drugId":"rc148","nct":"NCT07829549","title":"Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations","phases":["PHASE3"],"sponsor":"RemeGen Co., Ltd.","primaryCompletion":"2031-04","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"alectinib","nct":"NCT07829744","title":"Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations","phases":["PHASE2"],"sponsor":"Shanghai Zhongshan Hospital","primaryCompletion":"2030-06-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"sacituzumab-tirumotecan","nct":"NCT07829783","title":"A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)","phases":["PHASE3"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2031-11-17","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"romiplostim","nct":"NCT07829952","title":"Efficacy and Safety of Romiplostim N01 for Injection in Promoting Platelet Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation","phases":["PHASE2"],"sponsor":"The First Affiliated Hospital of Henan University of Science and Technology","primaryCompletion":"2028-06-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"pirtobrutinib","nct":"NCT07831395","title":"Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL","phases":["PHASE2"],"sponsor":"Institute of Hematology & Blood Diseases Hospital, China","primaryCompletion":"2030-12-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"megestrol","nct":"NCT07831902","title":"Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer","phases":["PHASE3"],"sponsor":"University College, London","primaryCompletion":"2030-12","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"nalirifox","nct":"NCT07831993","title":"Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer","phases":["PHASE2"],"sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","primaryCompletion":"2027-06-30","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"safusidenib","nct":"NCT07832123","title":"Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study","phases":["PHASE2"],"sponsor":"University of Zurich","primaryCompletion":"2029-03","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"imlunestrant","nct":"NCT07832227","title":"Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial","phases":["PHASE2"],"sponsor":"Dana-Farber Cancer Institute","primaryCompletion":"2028-12-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"foundationone-cdx","nct":"NCT07832630","title":"Saruparib in HRDsig+ Solid Tumors","phases":["PHASE2"],"sponsor":"Abramson Cancer Center at Penn Medicine","primaryCompletion":"2029-11-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"in10018","nct":"NCT07833202","title":"A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation","phases":["PHASE3"],"sponsor":"Shanghai Jeyou Pharmaceutical Co., Ltd.","primaryCompletion":"2029-04","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"surufatinib","nct":"NCT07833241","title":"Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC","phases":["PHASE2"],"sponsor":"Shanghai Zhongshan Hospital","primaryCompletion":"2028-09-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"trastuzumab-rezetecan","nct":"NCT07833657","title":"Combined Intrathecal and Systemic Therapy With Trastuzumab Rezetecan for Leptomeningeal Metastases","phases":["PHASE2"],"sponsor":"Jiuda Zhao","primaryCompletion":"2030-06","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"trastuzumab-rezetecan","nct":"NCT07836543","title":"Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer","phases":["PHASE2"],"sponsor":"Ming Chen","primaryCompletion":"2029-12","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"darolutamide","nct":"NCT07838753","title":"A Study Testing if Patients With Advanced Prostate Cancer Who Are Responding Well to Combination Treatment Can Safely Reduce Their Medication to a Single Hormone Therapy, Compared to Continuing Their Current Drugs","phases":["PHASE2"],"sponsor":"Kokilaben Dheerubhai Ambani Hospital and Research","primaryCompletion":"2029-09","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"belzutifan","nct":"NCT07840001","title":"Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma","phases":["PHASE2"],"sponsor":"Peter MacCallum Cancer Centre, Australia","primaryCompletion":"2029-04","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"camizestrant","nct":"NCT07840443","title":"Phase II Study of CAmizestrant in Resectable Endometrial Adenocarcinoma","phases":["PHASE2"],"sponsor":"University Health Network, Toronto","primaryCompletion":"2028-10-26","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"inotuzumab-ozogamicin","nct":"NCT07840976","title":"Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL","phases":["PHASE2"],"sponsor":"Institute of Hematology & Blood Diseases Hospital, China","primaryCompletion":"2028-05-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"recombinant-human-endostatin","nct":"NCT07841106","title":"Early Prophylactic Versus Late Salvage Recombinant Human Endostatin in Managing Radiosurgery-Induced Brain Injury for NSCLC Brain Metastases.","phases":["PHASE2"],"sponsor":"Jiangmen Central Hospital","primaryCompletion":"2028-04-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"palonosetron","nct":"NCT07841210","title":"Fosrolapitant and Palonosetron for Highly Emetogenic ADC-Induced Nausea and Vomiting in Solid Tumors","phases":["PHASE2"],"sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","primaryCompletion":"2028-01-31","kind":"new-study","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"zanidatamab","nct":"NCT07841873","title":"Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract Tumors","phases":["PHASE2"],"sponsor":"Anhui Provincial Hospital","primaryCompletion":"2028-06-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"octreotide-lanreotide","nct":"NCT07842172","title":"Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms","phases":["PHASE3"],"sponsor":"Washington University School of Medicine","primaryCompletion":"2034-11-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"utidelone","nct":"NCT07842276","title":"Utidelone Capsules Combined With Doxorubicin for Advanced Soft Tissue Sarcoma","phases":["PHASE2"],"sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","primaryCompletion":"2028-09-20","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-21","drugId":"polatuzumab-vedotin","nct":"NCT04594798","title":"A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL","phases":["PHASE2"],"sponsor":"University of Rochester","primaryCompletion":"2027-07-31","kind":"primary-completion","from":"2026-07-31","to":"2027-07-31"},{"detected":"2026-09-21","drugId":"tiragolumab","nct":"NCT04665856","title":"Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","phases":["PHASE3"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2023-08-31","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-21","drugId":"thyrotropin-alfa","nct":"NCT05128383","title":"Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids","phases":["PHASE2"],"sponsor":"Beth Israel Deaconess Medical Center","primaryCompletion":"2025-05-19","kind":"results-posted"},{"detected":"2026-09-21","drugId":"trifluridine-tipiracil","nct":"NCT06039202","title":"CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer","phases":["PHASE2"],"sponsor":"Holy Stone Healthcare Co., Ltd","primaryCompletion":"2030-10","kind":"status","from":"UNKNOWN","to":"SUSPENDED"},{"detected":"2026-09-21","drugId":"trifluridine-tipiracil","nct":"NCT06039202","title":"CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer","phases":["PHASE2"],"sponsor":"Holy Stone Healthcare Co., Ltd","primaryCompletion":"2030-10","kind":"primary-completion","from":"2025-02","to":"2030-10"},{"detected":"2026-09-21","drugId":"intismeran-autogene","nct":"NCT06077760","title":"A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)","phases":["PHASE3"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2030-06-25","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-21","drugId":"izalontamab-brengitecan","nct":"NCT06855771","title":"A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)","phases":["PHASE2"],"sponsor":"Bristol-Myers Squibb","primaryCompletion":"2028-12-29","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-21","drugId":"enfortumab-vedotin","nct":"NCT06906822","title":"PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients","phases":["PHASE2"],"sponsor":"Grupo Español Multidisciplinar de Melanoma","primaryCompletion":"2027-06","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-21","drugId":"iparomlimab-tuvonralimab","nct":"NCT06954116","title":"Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence","phases":["PHASE2"],"sponsor":"Tongji Hospital","primaryCompletion":"2028-12-31","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-21","drugId":"tarlatamab","nct":"NCT07061080","title":"Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab","phases":["PHASE2"],"sponsor":"Grupo Espanol de Tumores Neuroendocrinos","primaryCompletion":"2026-09-03","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"TERMINATED"},{"detected":"2026-09-21","drugId":"tarlatamab","nct":"NCT07061080","title":"Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab","phases":["PHASE2"],"sponsor":"Grupo Espanol de Tumores Neuroendocrinos","primaryCompletion":"2026-09-03","kind":"primary-completion","from":"2028-12","to":"2026-09-03"},{"detected":"2026-09-21","drugId":"romiplostim","nct":"NCT07421167","title":"A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)","phases":["PHASE2"],"sponsor":"Novartis Pharmaceuticals","primaryCompletion":"2029-01-18","kind":"primary-completion","from":"2028-05-09","to":"2029-01-18"},{"detected":"2026-09-21","drugId":"sacituzumab-tirumotecan","nct":"NCT07438626","title":"Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-06-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-21","drugId":"pucotenlimab","nct":"NCT07497919","title":"A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2029-05-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-21","drugId":"pluvicto","nct":"NCT07650240","title":"Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial","phases":["PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2030-12-30","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-21","drugId":"isatuximab","nct":"NCT07652905","title":"CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia","phases":["PHASE2"],"sponsor":"Institute of Hematology & Blood Diseases Hospital, China","primaryCompletion":"2029-06-30","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-21","drugId":"alpelisib","nct":"NCT07679269","title":"Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.","phases":["PHASE2"],"sponsor":"Novartis Pharmaceuticals","primaryCompletion":"2032-03-23","kind":"primary-completion","from":"2031-06-27","to":"2032-03-23"},{"detected":"2026-09-21","drugId":"nalirifox","nct":"NCT07827053","title":"Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer","phases":["PHASE2"],"sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","primaryCompletion":"2029-09-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-21","drugId":"glecirasib","nct":"NCT07827261","title":"A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","phases":["PHASE2"],"sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","primaryCompletion":"2028-12","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-21","drugId":"giredestrant","nct":"NCT07827573","title":"A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment","phases":["PHASE3"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2028-11-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-21","drugId":"vepugratinib","nct":"NCT07827612","title":"A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer","phases":["PHASE2"],"sponsor":"Eli Lilly and Company","primaryCompletion":"2028-07","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-21","drugId":"f182112","nct":"NCT07828522","title":"F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma","phases":["PHASE2"],"sponsor":"Institute of Hematology & Blood Diseases Hospital, China","primaryCompletion":"2027-10-09","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"vemurafenib","nct":"NCT01709292","title":"Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-09-30","kind":"primary-completion","from":"2026-09-30","to":"2028-09-30"},{"detected":"2026-09-17","drugId":"pralatrexate","nct":"NCT01947140","title":"Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies","phases":["PHASE1","PHASE2"],"sponsor":"Jennifer Amengual","primaryCompletion":"2022-09-01","kind":"status","from":"COMPLETED","to":"TERMINATED"},{"detected":"2026-09-17","drugId":"pralatrexate","nct":"NCT01947140","title":"Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies","phases":["PHASE1","PHASE2"],"sponsor":"Jennifer Amengual","primaryCompletion":"2022-09-01","kind":"results-posted"},{"detected":"2026-09-17","drugId":"flutamide","nct":"NCT03070886","title":"Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery","phases":["PHASE2","PHASE3"],"sponsor":"NRG Oncology","primaryCompletion":"2025-10-31","kind":"status","from":"COMPLETED","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-17","drugId":"olaparib","nct":"NCT04191135","title":"Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)","phases":["PHASE2"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2022-12-15","kind":"status","from":"COMPLETED","to":"TERMINATED"},{"detected":"2026-09-17","drugId":"dinutuximab","nct":"NCT04211675","title":"NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab","phases":["PHASE1","PHASE2"],"sponsor":"Nationwide Children's Hospital","primaryCompletion":"2026-12","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-17","drugId":"fedratinib","nct":"NCT04282187","title":"Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms","phases":["PHASE2"],"sponsor":"University of Washington","primaryCompletion":"2027-11-11","kind":"primary-completion","from":"2026-11-11","to":"2027-11-11"},{"detected":"2026-09-17","drugId":"tiragolumab","nct":"NCT04543617","title":"A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy","phases":["PHASE3"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2026-07-22","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-17","drugId":"tiragolumab","nct":"NCT04543617","title":"A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy","phases":["PHASE3"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2026-07-22","kind":"primary-completion","from":"2027-03-31","to":"2026-07-22"},{"detected":"2026-09-17","drugId":"dabrafenib","nct":"NCT04544111","title":"PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer","phases":["PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2027-09-02","kind":"primary-completion","from":"2026-09-02","to":"2027-09-02"},{"detected":"2026-09-17","drugId":"sonrotoclax","nct":"NCT04771130","title":"A Study of BGB-11417 in Participants With Myeloid Malignancies","phases":["PHASE1","PHASE2"],"sponsor":"BeOne Medicines","primaryCompletion":"2028-08-31","kind":"primary-completion","from":"2028-02-08","to":"2028-08-31"},{"detected":"2026-09-17","drugId":"glofitamab","nct":"NCT04889716","title":"CAR-T Followed by Bispecific Antibodies","phases":["PHASE2"],"sponsor":"Abramson Cancer Center at Penn Medicine","primaryCompletion":"2027-12-31","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-17","drugId":"abemaciclib","nct":"NCT04921904","title":"Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca","phases":["PHASE1","PHASE2"],"sponsor":"Baylor Research Institute","primaryCompletion":"2024-12-31","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-17","drugId":"abemaciclib","nct":"NCT04921904","title":"Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca","phases":["PHASE1","PHASE2"],"sponsor":"Baylor Research Institute","primaryCompletion":"2024-12-31","kind":"results-posted"},{"detected":"2026-09-17","drugId":"darolutamide","nct":"NCT05059236","title":"A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.","phases":["PHASE2"],"sponsor":"Bayer","primaryCompletion":"2025-05-30","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-17","drugId":"darolutamide","nct":"NCT05059236","title":"A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.","phases":["PHASE2"],"sponsor":"Bayer","primaryCompletion":"2025-05-30","kind":"results-posted"},{"detected":"2026-09-17","drugId":"foundationone-cdx","nct":"NCT05197322","title":"NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer","phases":["PHASE2"],"sponsor":"University College, London","primaryCompletion":"2029-11-01","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-17","drugId":"foundationone-cdx","nct":"NCT05197322","title":"NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer","phases":["PHASE2"],"sponsor":"University College, London","primaryCompletion":"2029-11-01","kind":"primary-completion","from":"2026-07-31","to":"2029-11-01"},{"detected":"2026-09-17","drugId":"fulvestrant","nct":"NCT05262400","title":"A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors","phases":["PHASE1","PHASE2"],"sponsor":"Pfizer","primaryCompletion":"2027-02-26","kind":"primary-completion","from":"2026-08-23","to":"2027-02-26"},{"detected":"2026-09-17","drugId":"dinutuximab","nct":"NCT05421897","title":"Rapid Administration Pilot for Infusing Dinutuximab","phases":["PHASE2"],"sponsor":"Children's Hospital Los Angeles","primaryCompletion":"2028-11","kind":"new-study","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-17","drugId":"trifluridine-tipiracil","nct":"NCT05438459","title":"GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites","phases":["PHASE1","PHASE2"],"sponsor":"Kyushu University","primaryCompletion":"2032-03-31","kind":"primary-completion","from":"2028-12-31","to":"2032-03-31"},{"detected":"2026-09-17","drugId":"lorigerlimab","nct":"NCT05475171","title":"Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-06-30","kind":"status","from":"SUSPENDED","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"olaparib","nct":"NCT05524935","title":"Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma","phases":["PHASE2"],"sponsor":"H. Lee Moffitt Cancer Center and Research Institute","primaryCompletion":"2027-07","kind":"primary-completion","from":"2026-07","to":"2027-07"},{"detected":"2026-09-17","drugId":"giredestrant","nct":"NCT05634499","title":"A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer","phases":["PHASE2"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2026-08-25","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-17","drugId":"giredestrant","nct":"NCT05634499","title":"A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer","phases":["PHASE2"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2026-08-25","kind":"primary-completion","from":"2026-08-28","to":"2026-08-25"},{"detected":"2026-09-17","drugId":"apalutamide","nct":"NCT05751941","title":"Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer","phases":["PHASE2"],"sponsor":"H. Lee Moffitt Cancer Center and Research Institute","primaryCompletion":"2026-07-04","kind":"primary-completion","from":"2026-07","to":"2026-07-04"},{"detected":"2026-09-17","drugId":"axicabtagene-ciloleucel","nct":"NCT05757219","title":"Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy","phases":["PHASE2"],"sponsor":"H. Lee Moffitt Cancer Center and Research Institute","primaryCompletion":"2027-02","kind":"primary-completion","from":"2026-06-20","to":"2027-02"},{"detected":"2026-09-17","drugId":"dalpiciclib","nct":"NCT05759572","title":"Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2026-07-21","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-17","drugId":"dalpiciclib","nct":"NCT05759572","title":"Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2026-07-21","kind":"primary-completion","from":"2025-11-01","to":"2026-07-21"},{"detected":"2026-09-17","drugId":"treosulfan","nct":"NCT05807932","title":"Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML","phases":["PHASE1","PHASE2"],"sponsor":"Heinrich-Heine University, Duesseldorf","primaryCompletion":"2029-04-30","kind":"primary-completion","from":"2026-01-31","to":"2029-04-30"},{"detected":"2026-09-17","drugId":"fruquintinib","nct":"NCT05831891","title":"Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma","phases":["PHASE2"],"sponsor":"RenJi Hospital","primaryCompletion":"2027-10-22","kind":"primary-completion","from":"2026-07-31","to":"2027-10-22"},{"detected":"2026-09-17","drugId":"nalirifox","nct":"NCT05851924","title":"A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)","phases":["PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2027-09-01","kind":"primary-completion","from":"2026-09-01","to":"2027-09-01"},{"detected":"2026-09-17","drugId":"tiragolumab","nct":"NCT05908786","title":"A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma","phases":["PHASE1","PHASE2"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2025-08-27","kind":"status","from":"COMPLETED","to":"TERMINATED"},{"detected":"2026-09-17","drugId":"tiragolumab","nct":"NCT05908786","title":"A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma","phases":["PHASE1","PHASE2"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2025-08-27","kind":"results-posted"},{"detected":"2026-09-17","drugId":"gemtuzumab-ozogamicin","nct":"NCT05955261","title":"A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia","phases":["PHASE2"],"sponsor":"St. Jude Children's Research Hospital","primaryCompletion":"2026-12","kind":"status","from":"SUSPENDED","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"foundationone-cdx","nct":"NCT06065748","title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","phases":["PHASE3"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2028-04-20","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-17","drugId":"foundationone-cdx","nct":"NCT06065748","title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","phases":["PHASE3"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2028-04-20","kind":"primary-completion","from":"2027-02-19","to":"2028-04-20"},{"detected":"2026-09-17","drugId":"arlocabtagene-autoleucel","nct":"NCT06297226","title":"Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma","phases":["PHASE2"],"sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","primaryCompletion":"2026-07-31","kind":"primary-completion","from":"2027-06-30","to":"2026-07-31"},{"detected":"2026-09-17","drugId":"enfortumab-vedotin","nct":"NCT06394570","title":"Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer","phases":["PHASE1","PHASE2"],"sponsor":"University of Texas Southwestern Medical Center","primaryCompletion":"2028-09-30","kind":"primary-completion","from":"2026-07-01","to":"2028-09-30"},{"detected":"2026-09-17","drugId":"bosutinib","nct":"NCT06423911","title":"Study of Olverembatinib (HQP1351) in Patients With CML-CP","phases":["PHASE3"],"sponsor":"Ascentage Pharma Group Inc.","primaryCompletion":"2027-06-30","kind":"primary-completion","from":"2025-12","to":"2027-06-30"},{"detected":"2026-09-17","drugId":"dalpiciclib","nct":"NCT06495515","title":"Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer","phases":["PHASE2"],"sponsor":"Tianjin Medical University Cancer Institute and Hospital","primaryCompletion":"2025-07-30","kind":"status","from":"UNKNOWN","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"tarlatamab","nct":"NCT06816394","title":"Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)","phases":["PHASE2"],"sponsor":"National Taiwan University Hospital","primaryCompletion":"2027-12-31","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"zolbetuximab","nct":"NCT06901531","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","phases":["PHASE3"],"sponsor":"Astellas Pharma Global Development, Inc.","primaryCompletion":"2028-09-30","kind":"primary-completion","from":"2027-03-31","to":"2028-09-30"},{"detected":"2026-09-17","drugId":"cetuximab-sarotalocan","nct":"NCT06943664","title":"Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer","phases":["PHASE2"],"sponsor":"Roswell Park Cancer Institute","primaryCompletion":"2027-05-01","kind":"status","from":"NOT_YET_RECRUITING","to":"WITHDRAWN"},{"detected":"2026-09-17","drugId":"carfilzomib","nct":"NCT06948084","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2028-02-28","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"tarlatamab","nct":"NCT07061080","title":"Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab","phases":["PHASE2"],"sponsor":"Grupo Espanol de Tumores Neuroendocrinos","primaryCompletion":"2028-12","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-17","drugId":"aglatimagene-besadenovec","nct":"NCT07332000","title":"A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec","phases":["PHASE2"],"sponsor":"Candel Therapeutics, Inc.","primaryCompletion":"2027-02","kind":"primary-completion","from":"2026-08","to":"2027-02"},{"detected":"2026-09-17","drugId":"tqb6411","nct":"NCT07367516","title":"Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","primaryCompletion":"2027-02","kind":"primary-completion","from":"2026-09","to":"2027-02"},{"detected":"2026-09-17","drugId":"naxitamab","nct":"NCT07537400","title":"Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5","phases":["PHASE2"],"sponsor":"Shaare Zedek Medical Center","primaryCompletion":"2028-06","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"botensilimab","nct":"NCT07551596","title":"Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2029-08-28","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"botensilimab","nct":"NCT07551596","title":"Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2029-08-28","kind":"primary-completion","from":"2026-09-30","to":"2029-08-28"},{"detected":"2026-09-17","drugId":"pivekimab-sunirine","nct":"NCT07581002","title":"A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)","phases":["PHASE2","PHASE3"],"sponsor":"AbbVie","primaryCompletion":"2032-06","kind":"primary-completion","from":"2032-05","to":"2032-06"},{"detected":"2026-09-17","drugId":"nalirifox","nct":"NCT07622771","title":"Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial","phases":["PHASE2"],"sponsor":"Sun Yat-sen University","primaryCompletion":"2028-06-30","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"lurbinectedin","nct":"NCT07625644","title":"BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)","phases":["PHASE3"],"sponsor":"SystImmune Inc.","primaryCompletion":"2030-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"enfortumab-vedotin","nct":"NCT07667335","title":"Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Fred Hutchinson Cancer Center","primaryCompletion":"2029-07-16","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"nintedanib","nct":"NCT07679893","title":"Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis","phases":["PHASE2"],"sponsor":"Mannkind Corporation","primaryCompletion":"2027-12-30","kind":"primary-completion","from":"2028-01-30","to":"2027-12-30"},{"detected":"2026-09-17","drugId":"sacituzumab-tirumotecan","nct":"NCT07718854","title":"Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer","phases":["PHASE2"],"sponsor":"Tufts Medical Center","primaryCompletion":"2036-09","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"sacituzumab-tirumotecan","nct":"NCT07718854","title":"Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer","phases":["PHASE2"],"sponsor":"Tufts Medical Center","primaryCompletion":"2036-09","kind":"primary-completion","from":"2032-03","to":"2036-09"},{"detected":"2026-09-17","drugId":"palifermin","nct":"NCT07775313","title":"Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM","phases":["PHASE1","PHASE2"],"sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","primaryCompletion":"2031-12-31","kind":"status","from":"NOT_YET_RECRUITING","to":"ENROLLING_BY_INVITATION"},{"detected":"2026-09-17","drugId":"ql1706","nct":"NCT07776080","title":"Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus","phases":["PHASE2"],"sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","primaryCompletion":"2027-10-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"azd5335","nct":"NCT07816666","title":"Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer","phases":["PHASE3"],"sponsor":"AstraZeneca","primaryCompletion":"2028-09-26","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"trastuzumab-rezetecan","nct":"NCT07817654","title":"Trastuzumab Combined With Retlirafusp Alfa in Treating HER2（Human Epidermal Growth Factor Receptor 2） 2+/3+ Gastric/Gastroesophageal Junction Adenocarcinoma After First-line Systemic Therapy Failure","phases":["PHASE2"],"sponsor":"Henan Cancer Hospital","primaryCompletion":"2027-12-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"envafolimab","nct":"NCT07818304","title":"SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLC","phases":["PHASE2"],"sponsor":"The First People's Hospital of Lianyungang","primaryCompletion":"2028-04","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"sctb35","nct":"NCT07819188","title":"SCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin Lymphoma","phases":["PHASE1","PHASE2"],"sponsor":"Sinocelltech Ltd.","primaryCompletion":"2028-09-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"epcoritamab","nct":"NCT07819214","title":"Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI","phases":["PHASE2"],"sponsor":"University of California, Irvine","primaryCompletion":"2028-10","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"sacituzumab-tirumotecan","nct":"NCT07819578","title":"Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC","phases":["PHASE2"],"sponsor":"Shaodong Hong","primaryCompletion":"2028-12-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"daraxonrasib","nct":"NCT07819838","title":"Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations","phases":["PHASE1","PHASE2"],"sponsor":"Children's Oncology Group","primaryCompletion":"2032-04-09","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"megestrol-progestins","nct":"NCT07820358","title":"Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer","phases":["PHASE2"],"sponsor":"The Methodist Hospital Research Institute","primaryCompletion":"2028-12-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"hs-20089","nct":"NCT07821606","title":"Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer","phases":["PHASE3"],"sponsor":"Hansoh BioMedical R&D Company","primaryCompletion":"2029-12-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"telisotuzumab-adizutecan","nct":"NCT07821684","title":"A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer","phases":["PHASE3"],"sponsor":"AbbVie","primaryCompletion":"2031-04","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"enfortumab-vedotin","nct":"NCT07822373","title":"A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer","phases":["PHASE2"],"sponsor":"University of Utah","primaryCompletion":"2034-11","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"sacituzumab-tirumotecan","nct":"NCT07823270","title":"Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma","phases":["PHASE2"],"sponsor":"Hebei Medical University Fourth Hospital","primaryCompletion":"2028-12","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"inca33890","nct":"NCT07823322","title":"A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy","phases":["PHASE2"],"sponsor":"Incyte Corporation","primaryCompletion":"2029-05-14","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"ql2107","nct":"NCT07823491","title":"Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall","phases":["PHASE3"],"sponsor":"Ohio State University Comprehensive Cancer Center","primaryCompletion":"2028-12-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"radioactive-iodine","nct":"NCT07823686","title":"Tracheal Replacement Using A Cryopreserved Aortic Allograft For R0 Resection In Locally Advanced Thyroid Cancer (TRITON 02 Tracheal Replacement In ThyrOid caNcer)","phases":["PHASE2"],"sponsor":"Assistance Publique - Hôpitaux de Paris","primaryCompletion":"2030-08-27","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"hpv-quadrivalent-vaccine","nct":"NCT07824310","title":"Immunogenicity and Safety of HPV-4 Vaccine With or Without Td Vaccine in Children","phases":["PHASE3"],"sponsor":"PT Bio Farma","primaryCompletion":"2026-12-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"hlx22","nct":"NCT07824869","title":"A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients","phases":["PHASE2"],"sponsor":"Shanghai Henlius Biotech","primaryCompletion":"2028-03-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"hs-20093","nct":"NCT07824882","title":"A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations","phases":["PHASE2"],"sponsor":"Hansoh BioMedical R&D Company","primaryCompletion":"2028-03-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"avutometinib-defactinib","nct":"NCT07824960","title":"Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma","phases":["PHASE1","PHASE2"],"sponsor":"University of Virginia","primaryCompletion":"2029-04","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"cevostamab","nct":"NCT07825064","title":"Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma","phases":["PHASE2"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2029-04-13","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"datopotamab-deruxtecan","nct":"NCT07825753","title":"Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2027-09-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"dalpiciclib","nct":"NCT07826052","title":"Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast Cancer","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2031-09-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-11","drugId":"dabrafenib","nct":"NCT04201457","title":"A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration","phases":["PHASE1","PHASE2"],"sponsor":"Pediatric Brain Tumor Consortium","primaryCompletion":"2026-10-01","kind":"primary-completion","from":"2026-03-31","to":"2026-10-01"},{"detected":"2026-09-11","drugId":"ipilimumab","nct":"NCT04464759","title":"A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma","phases":["PHASE1","PHASE2"],"sponsor":"Ravi Amaravadi, MD","primaryCompletion":"2026-11-13","kind":"primary-completion","from":"2026-07-31","to":"2026-11-13"},{"detected":"2026-09-11","drugId":"cabozantinib","nct":"NCT04820179","title":"Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer","phases":["PHASE2"],"sponsor":"University of Arizona","primaryCompletion":"2026-02-20","kind":"results-posted"},{"detected":"2026-09-11","drugId":"imlunestrant","nct":"NCT04923542","title":"SR & Abemaciclib With/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases","phases":["PHASE1","PHASE2"],"sponsor":"H. Lee Moffitt Cancer Center and Research Institute","primaryCompletion":"2026-11-05","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-11","drugId":"sacituzumab-govitecan","nct":"NCT05186974","title":"Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)","phases":["PHASE2"],"sponsor":"Gilead Sciences","primaryCompletion":"2027-03","kind":"primary-completion","from":"2026-09","to":"2027-03"},{"detected":"2026-09-11","drugId":"epcoritamab","nct":"NCT05201248","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma","phases":["PHASE1","PHASE2"],"sponsor":"Genmab","primaryCompletion":"2026-09","kind":"primary-completion","from":"2025-04","to":"2026-09"},{"detected":"2026-09-11","drugId":"lurbinectedin","nct":"NCT05229588","title":"Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations","phases":["PHASE2"],"sponsor":"HonorHealth Research Institute","primaryCompletion":"2025-08-04","kind":"results-posted"},{"detected":"2026-09-11","drugId":"inavolisib","nct":"NCT05306041","title":"Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer","phases":["PHASE2"],"sponsor":"GBG Forschungs GmbH","primaryCompletion":"2027-01","kind":"primary-completion","from":"2026-10","to":"2027-01"},{"detected":"2026-09-11","drugId":"amivantamab","nct":"NCT05845450","title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","phases":["PHASE2"],"sponsor":"Gruppo Oncologico del Nord-Ovest","primaryCompletion":"2027-05","kind":"primary-completion","from":"2026-05","to":"2027-05"},{"detected":"2026-09-11","drugId":"revumenib","nct":"NCT06229912","title":"A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-12-01","kind":"primary-completion","from":"2026-12-01","to":"2028-12-01"},{"detected":"2026-09-11","drugId":"mosunetuzumab","nct":"NCT06492837","title":"Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients","phases":["PHASE2"],"sponsor":"Fondazione Italiana Linfomi - ETS","primaryCompletion":"2028-09-15","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-11","drugId":"sotorasib","nct":"NCT06582771","title":"A Study of Sotorasib in People With Non-Small Cell Lung Cancer","phases":["PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2027-08","kind":"primary-completion","from":"2026-08","to":"2027-08"},{"detected":"2026-09-11","drugId":"relatlimab-nivolumab","nct":"NCT06708949","title":"A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-12-15","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-11","drugId":"relatlimab-nivolumab","nct":"NCT06708949","title":"A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-12-15","kind":"primary-completion","from":"2026-12-15","to":"2028-12-15"},{"detected":"2026-09-11","drugId":"lisocabtagene-maraleucel","nct":"NCT07098364","title":"ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma","phases":["PHASE1","PHASE2"],"sponsor":"Fred Hutchinson Cancer Center","primaryCompletion":"2030-10-04","kind":"status","from":"RECRUITING","to":"SUSPENDED"},{"detected":"2026-09-11","drugId":"degarelix","nct":"NCT07335796","title":"A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer","phases":["PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2030-01-09","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-11","drugId":"penpulimab","nct":"NCT07381075","title":"A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","phases":["PHASE2"],"sponsor":"West China Hospital","primaryCompletion":"2028-12-31","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-11","drugId":"penpulimab","nct":"NCT07381075","title":"A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","phases":["PHASE2"],"sponsor":"West China Hospital","primaryCompletion":"2028-12-31","kind":"primary-completion","from":"2028-10-01","to":"2028-12-31"},{"detected":"2026-09-11","drugId":"bicalutamide","nct":"NCT07593079","title":"Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer","phases":["PHASE2"],"sponsor":"Washington University School of Medicine","primaryCompletion":"2027-11-14","kind":"primary-completion","from":"2027-08-14","to":"2027-11-14"},{"detected":"2026-09-11","drugId":"olomorasib","nct":"NCT07814417","title":"A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation","phases":["PHASE2"],"sponsor":"Eli Lilly and Company","primaryCompletion":"2028-11","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-11","drugId":"sacituzumab-tirumotecan","nct":"NCT07815197","title":"Sacituzumab Tirumotecan as Second-Line Treatment for Penile Cancer","phases":["PHASE2"],"sponsor":"Latin American Cooperative Oncology Group","primaryCompletion":"2028-03","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-11","drugId":"dalpiciclib","nct":"NCT07815522","title":"Abiraterone With Dalpiciclib in Salivary Gland Carcinoma","phases":["PHASE2"],"sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","primaryCompletion":"2028-10-01","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-11","drugId":"enfortumab-vedotin","nct":"NCT07815665","title":"A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma","phases":["PHASE2","PHASE3"],"sponsor":"Summit Therapeutics","primaryCompletion":"2030-10-31","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-11","drugId":"crizotinib","nct":"NCT07816380","title":"A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 Versus Crizotinib in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer","phases":["PHASE3"],"sponsor":"Guangzhou JOYO Pharma Co., Ltd","primaryCompletion":"2028-12-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-10","drugId":"inotuzumab-ozogamicin","nct":"NCT03104491","title":"Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia","phases":["PHASE1","PHASE2"],"sponsor":"Leland Metheny","primaryCompletion":"2026-11","kind":"primary-completion","from":"2025-11","to":"2026-11"},{"detected":"2026-09-10","drugId":"cpx-351","nct":"NCT04061239","title":"Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML","phases":["PHASE2"],"sponsor":"GWT-TUD GmbH","primaryCompletion":"2026-08-07","kind":"status","from":"RECRUITING","to":"COMPLETED"},{"detected":"2026-09-10","drugId":"cpx-351","nct":"NCT04061239","title":"Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML","phases":["PHASE2"],"sponsor":"GWT-TUD GmbH","primaryCompletion":"2026-08-07","kind":"primary-completion","from":"2026-03","to":"2026-08-07"},{"detected":"2026-09-10","drugId":"tiragolumab","nct":"NCT04958811","title":"Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC","phases":["PHASE2"],"sponsor":"Georgetown University","primaryCompletion":"2026-11","kind":"primary-completion","from":"2026-07","to":"2026-11"},{"detected":"2026-09-10","drugId":"megestrol-progestins","nct":"NCT05316935","title":"GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients","phases":["PHASE2","PHASE3"],"sponsor":"Xiaojun Chen","primaryCompletion":"2028-03-30","kind":"primary-completion","from":"2026-03-30","to":"2028-03-30"},{"detected":"2026-09-10","drugId":"luspatercept","nct":"NCT05664737","title":"A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia","phases":["PHASE2"],"sponsor":"Bristol-Myers Squibb","primaryCompletion":"2027-07-16","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-10","drugId":"megestrol-progestins","nct":"NCT06379113","title":"GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients","phases":["PHASE2","PHASE3"],"sponsor":"Xiaojun Chen","primaryCompletion":"2028-03-30","kind":"primary-completion","from":"2026-03-30","to":"2028-03-30"},{"detected":"2026-09-10","drugId":"talquetamab","nct":"NCT06572605","title":"External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease","phases":["PHASE1","PHASE2"],"sponsor":"City of Hope Medical Center","primaryCompletion":"2030-01-18","kind":"status","from":"RECRUITING","to":"SUSPENDED"},{"detected":"2026-09-10","drugId":"serplulimab","nct":"NCT06576921","title":"Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction","phases":["PHASE2"],"sponsor":"Xijing Hospital","primaryCompletion":"2026-08-10","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-10","drugId":"serplulimab","nct":"NCT06576921","title":"Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction","phases":["PHASE2"],"sponsor":"Xijing Hospital","primaryCompletion":"2026-08-10","kind":"primary-completion","from":"2026-05-31","to":"2026-08-10"},{"detected":"2026-09-10","drugId":"ivonescimab","nct":"NCT07602855","title":"A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)","phases":["PHASE1","PHASE2"],"sponsor":"GlaxoSmithKline","primaryCompletion":"2029-06-21","kind":"primary-completion","from":"2029-07-05","to":"2029-06-21"},{"detected":"2026-09-10","drugId":"izalontamab-brengitecan","nct":"NCT07640789","title":"A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)","phases":["PHASE3"],"sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","primaryCompletion":"2030-12","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-10","drugId":"sacituzumab-tirumotecan","nct":"NCT07811752","title":"Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer","phases":["PHASE2"],"sponsor":"Shanghai Chest Hospital","primaryCompletion":"2027-12-31","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-10","drugId":"sonrotoclax","nct":"NCT07812246","title":"Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial","phases":["PHASE2"],"sponsor":"City of Hope Medical Center","primaryCompletion":"2028-08-13","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-10","drugId":"pirtobrutinib","nct":"NCT07812493","title":"Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement","phases":["PHASE2"],"sponsor":"Pengpeng Xu","primaryCompletion":"2028-09-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-10","drugId":"epcoritamab","nct":"NCT07814001","title":"Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy","phases":["PHASE2"],"sponsor":"The Lymphoma Academic Research Organisation","primaryCompletion":"2028-07","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-09","drugId":"trastuzumab-emtansine","nct":"NCT02675829","title":"Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers","phases":["PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2026-09-04","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-09","drugId":"trastuzumab-emtansine","nct":"NCT02675829","title":"Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers","phases":["PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2026-09-04","kind":"primary-completion","from":"2027-02","to":"2026-09-04"},{"detected":"2026-09-09","drugId":"optune","nct":"NCT02847559","title":"Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma","phases":["PHASE2"],"sponsor":"Northwestern University","primaryCompletion":"2025-08-11","kind":"status","from":"RECRUITING","to":"COMPLETED"},{"detected":"2026-09-09","drugId":"optune","nct":"NCT02847559","title":"Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma","phases":["PHASE2"],"sponsor":"Northwestern University","primaryCompletion":"2025-08-11","kind":"primary-completion","from":"2026-09","to":"2025-08-11"},{"detected":"2026-09-09","drugId":"encorafenib","nct":"NCT03803553","title":"Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer","phases":["PHASE3"],"sponsor":"Massachusetts General Hospital","primaryCompletion":"2026-12","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-09","drugId":"relatlimab-nivolumab","nct":"NCT04080804","title":"Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer","phases":["PHASE2"],"sponsor":"Dan Zandberg","primaryCompletion":"2026-04-13","kind":"primary-completion","from":"2027-10-01","to":"2026-04-13"},{"detected":"2026-09-09","drugId":"brentuximab-vedotin","nct":"NCT05039073","title":"Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors","phases":["PHASE2"],"sponsor":"Emory University","primaryCompletion":"2027-11-30","kind":"primary-completion","from":"2026-11-30","to":"2027-11-30"},{"detected":"2026-09-09","drugId":"autogene-cevumeran","nct":"NCT05968326","title":"A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC","phases":["PHASE2"],"sponsor":"Genentech, Inc.","primaryCompletion":"2031-01-01","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-09","drugId":"encorafenib","nct":"NCT06578559","title":"Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC","phases":["PHASE2"],"sponsor":"Gruppo Oncologico del Nord-Ovest","primaryCompletion":"2026-05-12","kind":"primary-completion","from":"2026-08-01","to":"2026-05-12"},{"detected":"2026-09-09","drugId":"lutathera","nct":"NCT06955169","title":"Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment","phases":["PHASE2"],"sponsor":"RTOG Foundation, Inc.","primaryCompletion":"2029-08","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-09","drugId":"disitamab-vedotin","nct":"NCT06966453","title":"A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Pfizer","primaryCompletion":"2027-10-25","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-09","drugId":"tarlatamab","nct":"NCT07005128","title":"A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)","phases":["PHASE3"],"sponsor":"Amgen","primaryCompletion":"2029-01-04","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-09","drugId":"tarlatamab","nct":"NCT07016230","title":"Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)","phases":["PHASE2"],"sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","primaryCompletion":"2027-05-18","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-09","drugId":"tarlatamab","nct":"NCT07016230","title":"Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)","phases":["PHASE2"],"sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","primaryCompletion":"2027-05-18","kind":"primary-completion","from":"2026-10-18","to":"2027-05-18"}]}